Compare HLSQ & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLSQ | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.0K | 976.1K |
| IPO Year | 2018 | 2000 |
| Metric | HLSQ | CRIS |
|---|---|---|
| Price | $0.16 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 292.0K | ★ 582.9K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 560.42 | 91.57 |
| EPS | ★ 3.56 | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.04 | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $0.15 | $0.33 |
| 52 Week High | $7.70 | $2,981.00 |
| Indicator | HLSQ | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 9.04 | 29.19 |
| Support Level | N/A | $0.33 |
| Resistance Level | $2.85 | $5.50 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.00 | 0.45 |
| Stochastic Oscillator | 0.63 | 97.66 |
Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.